patients (71.3%) had high risk symptoms (NG12). The sensitivity of FIT in this group at thresholds of 2 and 10 μg/g was 98.4% and 92.8%, respectively. The PPV was 9.1% and 16.3%, respectively. In contrast the sensitivity of FIT was significantly lower for low risk symptoms (DG30) at 91.5% and 84.5% at cut-offs of 2 or 10 μg/g respectively (p<0.01). The PPV for low risk symptoms at these thresholds was 7.7% and 16.0% respectively.

Conclusions This is the first study to report that at the lowest threshold of detectable blood (2 μg/g), FIT sensitivity is equivalent to the current gold standard investigation of colonoscopy. The results of this study support the use of FIT as an objective diagnostic tool to triage patients with both high and low risk CRC symptoms, reducing the number of unnecessary investigations.

Increasing Incidence of Young-Onset Colorectal Cancers in the UK and Rising Mortality in Rectal Cancers

Karl King Yong*, Moe Kyaw, Georgina Chadwick, Krishna Sundaram. London Northwest University Healthcare NHS Trust, London, UK; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Introduction The incidence of young-onset (<50 years old) colorectal cancer (CRC) is reported to be increasing in the western world. Studies on assessing trend in both the incidence and mortality are limited. Furthermore, there are no studies specific to United Kingdom (UK).

Design We performed a UK specific population-based study on young colon and rectal cancer incidence and mortality. Data on young-onset colon and rectal cancer incidence and mortality between 1996 and 2016 were obtained from the Cancer Research UK. Trends were analysed by Joinpoint Regression Program expressed as average annual percentage change (AAPC).

Results Incidence of young-onset colon and rectal cancer increased significantly in both male (colon cancer: 3.9 per 100,000 to 5.9 per 100,000; rectal cancer: 3.1 per 100,000 to 3.9 per 100,000) and female (colon cancer: 3.6 per 100,000 to 6.2 per 100,000; rectal cancer: 2.3 per 100,000 to 3.1 per 100,000). Mortality of young-onset colon cancer decreased significantly for male (1.7 per 100,000 to 1.1 per 100,000) but an insignificant decrease in female (1.4 per 100,000 to 1.1 per 100,000). However, the rectal cancer mortality increased significantly in both male (0.8 per 100,000 to 1.2 per 100,000) and female (0.6 per 100,000 to 1.0 per 100,000). (Figure 1)

Conclusion This is the first UK specific population-based study demonstrating the rising incidence of young-onset colon and rectal cancer and rising mortality from rectal cancer. There is a need for an increased awareness amongst clinicians in the UK and potential change to the current UK national bowel cancer screening guidelines.

The Evolution of Sporadic Colorectal Adenomas: Copy Number Alterations (CNA) in Poly Progressors vs Non-Progressors

Anisha Sukha*, Anne-Marie Baker, Marc Williams, Morgan Moorghen, Simon Leedham, Trevor Graham, Adam Humphries. Wolfson Unit for Endoscopy, St Mark’s Hospital, London, UK; Barts Cancer Institute, London, UK; Imperial College London, London, UK; University of Oxford, London, UK

Introduction 1 in 10 people in the UK have a detectable adenoma in the bowel wall. Most adenomas are asymptomatic and detected incidentally during national screening and surveillance programmes. People who have adenomas detected and removed are considered at an increased risk of colorectal cancer (CRC), with risk calculations based on adenoma size and multiplicity. Our current risk stratification model is unspecific and results in many patients having unnecessary surveillance procedures.

We hypothesise that prognostic biomarkers can be found through molecular analysis of adenomas removed at index colonoscopy, and there is a key role for copy number
alteration accrual in adenoma progression. A cost-effective test to more accurately define the cohort of patients that will never progress to CRC would reduce the burden of procedures on both the patient and NHS.

Methods FFPE adenoma tissue resected from patients who subsequently developed CRC (progressors) and matched adenomas from patients who remained cancer-free for 5+ years from the date of polypectomy (non-progressors) from a single-centre hospital archive (2008–2014) were analysed using low pass whole genome sequencing (LP-WGS). All adenomas were sequenced to a depth of >0.1x on an Illumina platform and CNA burden was investigated.

Results In this case-control study, progressors n=12 have a greater CNA burden than non-progressors n=37, with >0.05% of the genome altered in progressors and <0.01% in non-progressors, p=0.292. The number of distinct copy-number segments were analysed to compare the presence of candidate CNAs. Gains were seen in chromosomes 7, 9 and 12 (>25%) and losses in 18 (>10%) in the progressor cohort. In comparison, minimal chromosomal changes were seen in non-progressors.

Conclusions Adenomas from people who subsequently progress to cancer may have a greater percentage of the genome altered when compared to non-progressors, with the majority of non-progressor adenomas having little or no genomic alterations. Larger sample sizes are required to confirm this. In the future, it is conceivable that patients with high burden of genomic alterations in their adenomas would be offered more intensive follow-up surveillance that low-burden adenoma patients.